Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Ultragenyx (NASDAQ: RARE) reported an inducement grant of 20,317 restricted stock units (RSUs) to 17 newly hired non-executive officers, approved by the compensation committee and granted under the Ultragenyx Employment Inducement Plan.

The grant date was October 16, 2025 and the awards were disclosed October 24, 2025 as material inducements under Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years with 25% vesting on each anniversary, contingent on continuous employment.

NOVATO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 20,317 restricted stock units of the company’s common stock to 17 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of October 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370

FAQ

How many RSUs did Ultragenyx grant on October 16, 2025 under Nasdaq Rule 5635(c)(4)?

Ultragenyx granted 20,317 restricted stock units on October 16, 2025 as inducement awards.

How many employees received the inducement RSUs from Ultragenyx (RARE)?

17 newly hired non-executive officers received the restricted stock unit awards.

What is the vesting schedule for the Ultragenyx RSUs granted October 16, 2025?

The RSUs vest over four years with 25% of shares vesting each anniversary, subject to continuous employment.

Why did Ultragenyx disclose the grant under Nasdaq Listing Rule 5635(c)(4)?

The company disclosed the awards as material inducements for newly hired employees in accordance with Nasdaq Listing Rule 5635(c)(4).

Will Ultragenyx shareholders see immediate dilution from the 20,317 RSUs?

The disclosure notes the grant amount and vesting but does not state immediate share issuance; dilution would occur only as RSUs vest and shares are issued.